Overview
Neonatal antiphospholipid syndrome is not directly addressed in the provided abstracts. The abstracts discuss a distinct neonatal syndrome characterized by intrauterine growth retardation, lactic acidosis, aminoaciduria, and liver hemosiderosis, but do not cover antiphospholipid syndrome in neonates. 1Diagnosis
No specific diagnostic criteria provided for neonatal antiphospholipid syndrome in the given abstracts.
The described syndrome involves clinical features like intrauterine growth retardation, lactic acidosis, and aminoaciduria, but these are not linked to antiphospholipid antibodies 1.Management
No specific treatments for neonatal antiphospholipid syndrome are mentioned in the abstracts.
Management of the described neonatal syndrome (not antiphospholipid) would likely involve supportive care, addressing metabolic acidosis, and managing liver complications, though specific interventions are not detailed 1.Special Populations
No information provided regarding neonatal antiphospholipid syndrome in pregnancy, pediatrics, elderly, or comorbidities.
The abstracts focus on a Finnish cohort with a specific genetic neonatal syndrome, lacking broader population or comorbidity considerations 1.Key Recommendations
Genetic counseling may be considered for families with a history of the described neonatal syndrome due to its autosomal recessive inheritance pattern (Evidence: Expert opinion) 1.
Early recognition and supportive management of metabolic derangements (e.g., lactic acidosis) are crucial in neonates with similar presentations (Evidence: Moderate) 1.
Further research is needed to establish diagnostic criteria and treatment protocols for neonatal antiphospholipid syndrome, as current abstracts do not provide sufficient evidence (Evidence: Expert opinion) 1.References
1 Visapää I, Fellman V, Varilo T, Palotie A, Raivio KO, Peltonen L. Assignment of the locus for a new lethal neonatal metabolic syndrome to 2q33-37. American journal of human genetics 1998. link